duminică, 11 decembrie 2011

Mayo Clinic: Obese Patients With HER2-Positive Breast Cancer May Have Worse Outcomes

Main Category: Breast Cancer
Also Included In: Obesity / Weight Loss / Fitness
Article Date: 11 Dec 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth.

"Not only did obese women have poorer outcomes given several different therapies tested to treat HER2-positive breast cancer, but we know that obese patients in our study had larger tumors and were more likely to have had cancer detected in their lymph nodes, compared to patients who were not obese," says the study's lead author, Jennifer Crozier, M.D., a medical resident.

"While other studies have looked at the effect of body weight on treatment outcome for estrogen receptor-positive breast cancer, no one has examined this variable in the HER2-positive subtype, which accounts for about one-third of all breast cancers," says Dr. Crozier.

Researchers used data from the North Central Cancer Treatment Group N9831 study for their analysis. This phase III randomized clinical trial tested three different options for treatment of early stage HER2-positive breast cancer: chemotherapy alone (Arm A); chemotherapy followed by Herceptin for a year (Arm B); and chemotherapy plus Herceptin, followed by Herceptin for a year (Arm C).

In a review of data from 3,017 patients, researchers found that, considering all three treatment arms together, obese patients -- those with a body mass index (BMI) of 30 or more -- had worse outcomes than patients with a BMI less than 30, although these trends were not statistically significant.

Researchers then calculated disease-free survival for each study arm for normal weight, overweight and obese patients, and found that patients fared best in Arm C. In this arm, the difference between BMI and outcome was not statistically significant, Dr. Crozier says. Herceptin was powerful enough to provide an equal benefit in patients with vastly varying body weights, she says.

"We are continually searching for approaches that will help our patients have the best outcome possible after their diagnosis of breast cancer, and this study suggests that excess body weight may make a difference," says senior investigator Edith Perez, M.D., director of Mayo Clinic's breast program in Florida.

The study was funded by the National Institutes of Health, Genentech, Bayer, and the Breast Cancer Research Foundation.

The authors declare no conflicts of interest.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our breast cancer section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Mayo Clinic. "Mayo Clinic: Obese Patients With HER2-Positive Breast Cancer May Have Worse Outcomes." Medical News Today. MediLexicon, Intl., 11 Dec. 2011. Web.
11 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here